Contineum Therapeutics (CTNM) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Contineum Therapeutics is expected to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.56) per share and revenue of $7.50 million.
• Shares of CTNM recently traded at $5.88, with a market capitalization of approximately $152.12 million and a twelve month high of $20.55.
• Analysts have mixed views on the stock, with recent price targets ranging from $20.00 to $31.00, and a consensus rating of "Buy."

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect Contineum Therapeutics to post earnings of ($0.56) per share and revenue of $7.50 million for the quarter.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06). On average, analysts expect Contineum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Contineum Therapeutics Stock Performance

Contineum Therapeutics stock traded up $0.34 during trading hours on Thursday, hitting $6.67. 93,565 shares of the stock were exchanged, compared to its average volume of 130,667. Contineum Therapeutics has a 12 month low of $3.35 and a 12 month high of $20.55. The business's 50-day moving average is $4.50 and its two-hundred day moving average is $5.78. The stock has a market capitalization of $172.48 million, a P/E ratio of -3.05 and a beta of 1.04.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Contineum Therapeutics stock. Dynamic Technology Lab Private Ltd bought a new stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 16,838 shares of the company's stock, valued at approximately $118,000. Dynamic Technology Lab Private Ltd owned about 0.07% of Contineum Therapeutics at the end of the most recent quarter.

Analyst Ratings Changes

CTNM has been the topic of a number of recent analyst reports. Morgan Stanley lowered their target price on shares of Contineum Therapeutics from $25.00 to $20.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $31.00 price target on shares of Contineum Therapeutics in a research note on Thursday, May 15th. Finally, William Blair assumed coverage on Contineum Therapeutics in a research report on Friday, June 20th. They set an "outperform" rating on the stock. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $22.50.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).